Dupixent (dupilumab) is an injectable biologic sold by Sanofi and Regeneron. FDA labeling covers eczema, asthma, COPD, chronic rhinosinusitis with nasal polyps, allergic fungal rhinosinusitis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria and bullous pemphigoid. Most adults inject 300 mg every two weeks, so a carton of two prefilled pens is about one month of treatment.
That schedule is what makes Dupixent unusual among high-cost biologics: it has a clean monthly price you can actually compare across pharmacies. It is also the one drug in this group where a pharmacy discount card measurably changes the number. Every figure below was verified on September 2, 2026. This page covers money and paperwork only, not whether the drug is appropriate for you.
What Does Dupixent Cost Without Insurance?
Sanofi publishes Dupixent’s list price on the drug’s own cost page and defines a monthly supply as two injections. Retail cash figures come from SingleCare’s live Dupixent page, prices updated September 2, 2026, for a carton of two 300 mg per 2 mL pens. The Medicare row comes from CMS’s Medicare Part D Spending by Drug dataset, data year 2024, released June 25, 2026.
| Option | Low | Average / typical | High |
|---|---|---|---|
| Dupixent, average retail cash (no card) | $5,469.58 | $5,469.58 | $5,469.58 |
| Dupixent, cash with a discount card | $4,012.79 | $4,215.80 | $4,339.84 |
| Sanofi published list price, monthly supply | $4,193.03 | $4,193.03 | $4,193.03 |
| Medicare Part D average per fill, 2024 (pen) | $4,005.66 | $4,005.66 | $4,005.66 |
| Medicare Part D average per fill, 2024 (syringe) | $4,021.29 | $4,021.29 | $4,021.29 |
| DUPIXENT MyWay Copay Card (commercial insurance only) | $0 | $0 | $0 |
| DUPIXENT MyWay Patient Assistance Program (approved applicants) | $0 | $0 | $0 |
The cross-source range for one uncovered month is roughly $4,013 to $5,470. One note on the discount-card row: SingleCare’s per-pharmacy figures move between sessions, so treat the spread as illustrative of how much pharmacies differ rather than as a fixed quote for any named chain. The average retail and the as-low-as figures are the stable ones.
List price is not the counter price
Sanofi’s stated list price, also called wholesale acquisition cost, is what the manufacturer charges wholesalers. Average retail cash price includes the pharmacy’s markup on top of that, which is why SingleCare’s $5,469.58 sits about $1,277 above the $4,193.03 list figure.
What is genuinely unusual here is that the discount-card price, as low as $4,012.79, lands slightly below list. On most brand-only biologics a card shaves nothing. On Dupixent it is worth roughly $1,457 a month against average retail, so it is the single cheapest thing an uninsured person can do in five minutes.
What Medicare’s own data shows
CMS’s Part D data is a useful reality check because it is a national average of what actually got paid, not an advertised price. In 2024, Part D covered 450,526 Dupixent pen fills for 65,541 beneficiaries at an average of $4,005.66 per fill and $1.80 billion in total spending. Average spending per beneficiary was $27,534.73 for the year, which is lower than a full 13-carton run because many people start mid-year or stop.
What Drives the Price
There is no biosimilar. FDA’s biosimilar product list, content current as of August 4, 2026, contains no dupilumab product. Compare that to Humira, which now has ten adalimumab biosimilars and a cheapest cash option in the low hundreds. Until a dupilumab biosimilar launches, there is nothing cheaper to switch the prescription to.
Your dosing schedule, which the condition sets. FDA labeling puts most adults at 300 mg every two weeks after a 600 mg loading dose, but eosinophilic esophagitis dosing for patients 40 kg or more is 300 mg weekly, and several pediatric weight bands are every four weeks. Weekly dosing roughly doubles the monthly cost and every-four-week dosing roughly halves it, so confirm the schedule on your prescription before you budget.
Which pharmacy fills it. SingleCare’s September 2026 data shows a spread of about $327 a month between the cheapest and priciest chains on the identical carton. That is real money over a year, and it is the one variable you control without paperwork.
Whether a card is applied at all. The difference between walking in cold and walking in with a discount card is roughly $1,457 per carton. Nothing else on this page except the assistance programs beats that.
Your insurance type, not just whether you have insurance. The copay card requires commercial coverage. The free-drug program requires limited or no coverage. People on Medicare Part D are locked out of the card by federal rules but are explicitly named as eligible for the assistance program, which is why some Medicare enrollees end up better positioned than people with thin commercial plans.
Cash Price vs. Insurance
If you are uninsured, no cash-shopping strategy comes close to the DUPIXENT MyWay Patient Assistance Program. Sanofi’s prescriber-facing page states the program can provide Dupixent at no cost to eligible patients who are uninsured, underinsured or on Medicare Part D, and that approved patients may receive free shipments of up to an 84-day supply for up to 12 months, with the option to reapply. Medicare Part D patients have to reapply each calendar year by December 31.
If you are commercially insured, run the claim and use the copay card. Sanofi advertises as little as $0 per fill for eligible commercially insured patients, subject to a program maximum per calendar year. Sanofi’s own coverage tool states that roughly 68% of commercially insured Dupixent patients pay between $0 and $100 a month and about 32% pay more than $100.
The trap in the middle is a commercial plan that runs an accumulator or maximizer program. Those designs capture manufacturer assistance instead of crediting it to your deductible, and Sanofi’s posted terms note the program may change its terms for patients on such plans. If a pharmacy quotes you something that matches nothing on this page, our fair price checker is a quick sanity test before you pay.
How to Pay Less
-
Ask a DUPIXENT MyWay case manager about the Patient Assistance Program by name. It is the only route that reliably takes an uninsured patient to $0. Sanofi reviews eligibility case by case and does not publish income thresholds, so the only way to find out is to apply.
-
Run a discount card on the exact carton before you fill. This is the rare biologic where cards work, worth roughly $1,457 a month against average retail. Our comparison of GoodRx vs. SingleCare shows how to check both on the same NDC in a couple of minutes.
-
Confirm your dose schedule and strength before you budget. A 200 mg every-four-week schedule and a 300 mg weekly schedule are both on the FDA label, and they price completely differently. Ask the prescriber which one your prescription is written for.
-
Do not count on a copay foundation if you are uninsured. The HealthWell Foundation states plainly that you must have some form of health insurance that covers part of your treatment, that drug discount cards do not qualify as insurance, and that it refers patients without prescription insurance to manufacturer assistance programs instead. That is the standard rule across copay charities, and knowing it saves you an application cycle.
-
Price the visits and monitoring separately. A free or sliding-scale clinic can handle the prescribing and follow-up visits that keep the prescription active, and our guide to dermatologist costs without insurance covers what a specialist visit runs on cash.
-
Deal with any bill that already landed. If a specialty pharmacy or hospital bill arrived before assistance was approved, our medical bill negotiation guide covers what to say, and hospital charity care may wipe out the facility side entirely.
Bottom Line
Budget $4,013 to $5,470 for one month of Dupixent if you pay cash in September 2026, against a Sanofi list price of $4,193.03 per carton and a 2024 Medicare Part D average of $4,005.66 per fill. Over a year at the adult every-two-week dose, that is roughly $54,500 at list and about $71,100 at average retail.
The number that actually matters, though, is zero, and two different programs can get you there depending on your coverage: the copay card if you have commercial insurance, and the MyWay Patient Assistance Program if you have little or none. For other biologics priced the same way, see our guides to Skyrizi and Tremfya, and for the oral options in the same corner of the market, Rinvoq and Otezla. If you want to see what happens to a biologic’s price once cheaper equivalents finally arrive, Humira is the case study.